

1 Auxotonic to Isometric Contraction Transitioning in a Beating Heart Causes Myosin Step-Size to
2 Down Shift

3

4

5 Thomas P. Burghardt^{1,2,*}, Xiaojing Sun¹, Yihua Wang¹, and Katalin Ajtai¹

6

7

8 November 2016

9 Revised January 2017

10 Revised February 2017 Accepted 12 March 2017

11

12 ¹ Department of Biochemistry and Molecular Biology, Mayo Clinic Rochester, Rochester, MN
13 55905

14 ² Department of Physiology and Biomedical Engineering, Mayo Clinic Rochester, Rochester,
15 MN 55905

16 * To whom correspondence should be addressed. Email: burghardt@mayo.edu

17

18

19 Short Title: Myosin Step-Size Down Shifting in Contraction

20

21

22 **Abstract**

23 Myosin motors in cardiac ventriculum convert ATP free energy to the work of moving blood
24 volume under pressure. The actin bound motor cyclically rotates its lever-arm/light-chain
25 complex linking motor generated torque to the myosin filament backbone and translating actin
26 against resisting force. Previous research showed that the unloaded in vitro motor is described
27 with high precision by single molecule mechanical characteristics including unitary step-sizes of
28 approximately 3, 5, and 8 nm and their relative step-frequencies of approximately 13, 50, and
29 37%. The 3 and 8 nm unitary step-sizes are dependent on myosin essential light chain (ELC) N-
30 terminus actin binding. Step-size and step-frequency quantitation specifies in vitro motor
31 function including duty-ratio, power, and strain sensitivity metrics. In vivo, motors integrated
32 into the muscle sarcomere form the more complex and hierarchically functioning muscle
33 machine. The goal of the research reported here is to measure single myosin step-size and step-
34 frequency in vivo to assess how tissue integration impacts motor function.

35 A photoactivatable GFP tags the ventriculum myosin lever-arm/light-chain complex in the
36 beating heart of a live zebrafish embryo. Detected single GFP emission reports time-resolved
37 myosin lever-arm orientation interpreted as step-size and step-frequency providing single myosin
38 mechanical characteristics over the active cycle. Following step-frequency of cardiac
39 ventriculum myosin transitioning from low to high force in relaxed to auxotonic to isometric
40 contraction phases indicates that the imposition of resisting force during contraction causes the
41 motor to down-shift to the 3 nm step-size accounting for >80% of all the steps in the near-
42 isometric phase. At peak force, the ATP initiated actomyosin dissociation is the predominant
43 strain inhibited transition in the native myosin contraction cycle. The proposed model for motor
44 down-shifting and strain sensing involves ELC N-terminus actin binding.

45 Overall, the approach is a unique bottom-up single molecule mechanical characterization of a
46 hierarchically functional native muscle myosin.

47

48

49

50 KEYWORDS

51 Transgenic zebrafish cardiac ventriculum

52 Single cardiac ventriculum myosin detection in vivo

53 Native cardiac myosin mechanical characteristics

54 Strain dependent cardiac myosin detachment from actin

55 In vivo zebrafish cardiac myosin step-size

56 In vivo zebrafish cardiac myosin step-frequency

57

58 **Introduction**

59 The myosin motor protein powers the beating heart with transduction of ATP to
60 mechanical work. Rationalizing “bottom-up” single myosin mechanics with “top-down” whole
61 animal muscle physiology is indispensable to solving myosin’s structure/function paradigm for
62 creating an ensemble capable nanomotor and to providing the insight into muscle disease
63 mechanisms demanded by translational science. A time-resolved *in vivo* imaging approach
64 characterizes single myosin mechanics in contracting striated muscle of live zebrafish embryos.
65 It provides the means for linking bottom-up myosin characteristics to top-down muscle
66 physiology or phenotype in the zebrafish embryo model for human muscle.

67 The myosin transducer has a globular head (subfragment 1 or S1) and tail domain that
68 forms myosin dimers and assembles into thick filaments. Thick filaments interdigitate with actin
69 thin filaments in striated muscle and slide relatively during contraction [1]. S1 contains ATP and
70 actin binding sites and a swinging lever-arm that cyclically applies tension to power filament
71 sliding while myosin is strongly actin bound. The lever-arm converts torque generated in the
72 motor into linear displacement (step-size) and undergoes strain due to the resisting force. Strain
73 affects the lever-arm and the bound essential and regulatory light chains (ELC and RLC). RLC
74 stabilizes the lever-arm [2] and disease implicated RLC mutants lower velocity, force, and strain
75 sensitivity suggesting they alter lever-arm processing of stress [3]. The ELC N-terminus binds
76 actin to modulate myosin functionality [4] and step-size in cardiac muscle [5].

77 In published work, we tagged human ventricular cardiac RLC (MYL2) at the C-terminus
78 with green fluorescent protein (HCRLC-GFP) then exchanged the chimera into permeabilized
79 skeletal [6] or cardiac papillary muscle fibers [7]. Extensively and specifically exchanged
80 myosin in these fibers supports native isometric contraction implying the GFP tag does not affect
81 muscle contraction. The photoactivatable variant, HCRLC-PAGFP, was individually activated in
82 the exchanged papillary muscle fibers isolating single myosins *in situ*. Super-resolved orientation
83 of single myosin lever-arms was measured from fibers in rigor, relaxation, and active isometric
84 conditions. Single molecule orientation was also measured for the exchanged HCRLC-PAGFP
85 modified by disease linked mutations to the HCRLC [3]. The exchanged mutant HCRLC
86 lowered lever-arm stiffness and impaired lever-arm transduction/mechanical-coupling.

87 The zebrafish embryo is transparent to visible light allowing deep imaging using wide
88 field fluorescence microscopy with highly inclined (HILO) illumination [8]. In the present work,
89 new transgenic zebrafish were created by inserting the HCRLC-GFP or HCRLC-PAGFP gene
90 into the zebrafish genome and using the *cmlc2* promoter to drive gene expression in the heart [9].
91 Transgenic zebrafish embryos had visible GFP expression confined to the heart ventricle and
92 arranged in the striated pattern characteristic to myosin in cardiac muscle fiber sarcomeres
93 indicating specific myosin binding. Embryonic and adult transgenic zebrafish have normal heart
94 phenotype and function. At 3-4 days post fertilization (dpf), embryos expressing HCRLC-
95 PAGFP were imaged using HILO to detect single cardiac myosin lever-arms in the beating heart.
96 The native embryonic heart runs with ~120 beats per min (bpm) at room temperature. We slowed
97 heart rate to ~60 bpm using a reversible anesthetic treatment affecting nervous controlled cardiac
98 pacing and imaged single cardiac myosins at 10 frames per second. Usually one heart cycle was
99 quantitated in 10 sequential images. Each image acquired light for slightly less than 100 ms. This
100 sampling rate captured and quantitated interesting mechanical features of the single functioning
101 cardiac myosins while faster frame rates failed to provide an adequate signal to noise (S/N) ratio
102 profile for quantitation. Control imaging experiments were also conducted on relaxed hearts
103 temporarily stopped by a higher dose anesthetic treatment. The heart contraction cycle separated
104 into late relaxed (diastole and full heart), auxotonic active (early systole where cardiac force
105 exceeds load), and isometric active (late systole before ejection where cardiac force equals load)
106 phases with distinct myosin mechanical characteristics. Comparison of single myosin mechanics
107 in auxotonic and isometric contraction suggests a new paradigm for mechanical regulation of
108 force/velocity.

109 Myosin mechanical functionality in vitro and at the single molecule level precisely
110 characterizes the essential myosin structure/function paradigm but in the absence of the other
111 motors and proteins in the muscle sarcomere. The native myosin is more complex with potential
112 for hierarchical coordinated functionality because of its structured environment. The zebrafish
113 embryo model system provides opportunity for single molecule mechanical characterization of a
114 naturally integrated cardiac myosin. We measure in vivo cardiac myosin lever-arm rotation and
115 interpret data as the step-size and step-frequency. These metrics uniquely specify native myosin
116 functionality for an unprecedented view into how tissue integration shapes motor function.

117 **Materials and methods**

118 **A. Zebrafish sample preparations**

119 **Ethics.**

120 Zebrafish embryos were produced and used in this study with approval from the Mayo
121 Clinic Rochester Institutional Animal Care and Use Committee (protocol A47113).

122

123 **Zebrafish adult ventricular cardiac myosin extraction and preparation.**

124 2-6 adult wild type (WT or Zmys) 11 month old dominant leopa zebrafish were obtained
125 from the Mayo Clinic Zebrafish Core Facility. Fish were anesthetized for 3-5 minutes using
126 tricaine methanesulfonate (MS-222, 168 mg/L) then euthanized. Hearts were dissected by using
127 forceps and the ventricle placed into 1.5 ml eppendorf tubes containing 40 μ L/(5 hearts) SDS
128 sample buffer (0.125 M Tris-HCL pH 6.8, 10% glycerol, 2% SDS, 5% ²-mercaptoethanol, and
129 0.5 mg/ml bromophenol blue). The tubes were vortexed, pelleted in the centrifuge, and heated to
130 95 °C for 5 minutes. The pellet was homogenized by hand using a pellet pestle then incubated at
131 room temperature for 30 min. The supernatant containing the extracted and denatured cardiac
132 tissue proteins were heated again to 95 °C for 5 minutes and loaded to a gel or stored in the
133 freezer at -20 °C.

134

135 **Zebrafish embryo cardiac myosin extraction.**

136 Dpf 6 embryos (~80) were anesthetized for 3-5 minutes using tricaine then euthanized.
137 Embryos were transfer into E3 water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM
138 MgSO₄, 10⁻⁵ % methylene blue) onto a 16-well glass slide. The hearts were dissected under the
139 microscope using two insulin needles and excess buffer removed. We added 2-3 μ L 3% SDS
140 sample buffer (without bromophenol blue) to each well then transferred the tissue to a 1.5 ml
141 Eppendorf tube on ice. The tissue sample was centrifuged at low speed, denatured at 95°C for 5

142 min, sonicated for 2 min, incubated at room temperature for 30 min and then centrifuged with
143 14000g for 10 min at 4°C. Supernatant containing solubilized protein was concentrated using ice
144 cold 20% trichloro acetic acid (TCA) precipitation, vortexed and incubated for 30 minutes on
145 ice, centrifuged for 30 minutes at top speed in a microcentrifuge at 4 °C then the supernatant was
146 carefully removed to avoid disturbing the pellet. We added 0.5 ml cold acetone to the pellet to
147 remove traces of TCA, vortexed briefly, centrifuged for 15 minutes at top speed in
148 microcentrifuge at 4 °C, removed supernatant and dried the pellet with nitrogen gas. Dried pellet
149 was resuspended in 2% SDS sample buffer with bromophenol blue, boiled, centrifuged at low
150 speed to remove particulate matter, then loaded on the gel or stored at -20 °C.

151

152 **Transgenic animals expressing HCRLC-GFP or HCRLC-PAGFP.**

153 We coinjected transposase mRNA and plasmid containing a Tol2 construct with the
154 zebrafish *cmlc2* enhancer and the gene for HCRLC-GFP or HCRLC-PAGFP into the cytoplasm
155 of one-cell-stage embryos. *Cmlc2* enhancer drives HCRLC-(PA)GFP expression specifically in
156 cardiac muscle [9]. At 3-4 dpf, we screened embryos for green fluorescence excited by 405 nm
157 transmitted light using a 10X objective. Selected embryos exhibiting (PA)GFP expression were
158 raised to produce F0 adults according to standard rearing protocols in the zebrafish core facility.
159 After three months, the founder fish (F0) were screened by outcrossing with wild type. The F1
160 embryo offspring were used for experiments or grown to maturity for an F2 generation.

161 Transgenic zebrafish had visible (PA)GFP expression confined to the heart and in the
162 striated pattern similar to that in skeletal muscle of transiently expressed HCRLC-(PA)GFP
163 using the *UNC-45b* enhancer [10, 11]. Wild type fish were incrossed as control and F1
164 transgenic fish were outcrossed with wild type producing F2 embryos. F2 transgenic GFP(+) or
165 GFP(-) (TgGFP(+) or TgGFP(-)) embryos having strong or weak (PA)GFP expression in the
166 heart were selected at 3-4 dpf. Transgenic animals are indicated by TgGFP for either GFP or
167 PAGFP chromophores. Single myosin imaging is always performed with the PAGFP containing
168 isoform.

169 Embryos were usually treated with 0.5 mM 1-phenyl 2-thiourea (PTU) at 1 dpf to inhibit
170 melanogenesis. Experiments were conducted at room temperature (20-22 °C).

171

172 **Cardiac functionality in zebrafish embryos.**

173 Zebrafish embryo cardiac function was estimated at 3 dpf using an ellipsoid of revolution
174 to approximate ventricle shape with long (*a*) and short (*b*) axes measured from movies of the
175 functioning hearts [12]. Cardiac performance was described by 4 parameters consisting of heart
176 rate, ventricle shortening fraction (SF), ventricle end systolic (smallest) volume, and ventricle
177 end diastolic (largest) volume. The shortening fraction measures the maximum change in *a*
178 relative to the longest *a* over a contraction cycle. Measurements were conducted on WT and
179 transgenic embryos with and without PTU treatment.

180

181 **Quantitation of HCRLC-(PA)GFP tagged myosin in zebrafish embryos.**

182 Native zebrafish cardiac ventricular regulatory light chain ZRLC and HCRLC-(PA)GFP
183 protein expression levels were measured using SDS-PAGE of expressed and extracted proteins.
184 Quantities of purified embryonic myosin were too low to detect quantitatively on a Sypro Ruby
185 stained gel hence we combined Sypro Ruby staining and protein immunoblotting. Purified native
186 adult zebrafish ventricular cardiac myosin and an *in vitro* expressed HCRLC standard were run
187 on adjacent lanes on an SDS-PAGE gel that was stained with Sypro Ruby. Intensity for the
188 ZRLC and HCRLC bands were compared to estimate ZRLC quantity. Protein bands from an
189 identical gel were transferred to a membrane for Western blotting using a primary RLC antibody
190 (1:1000 dilution, product number 10906-1-AP, Proteintech, Chicago, IL)[13]. Antibody staining
191 of the known amounts of ZRLC and HCRLC validated and calibrated the standardized
192 immunoblotting protocol for their detection.

193 Myosin extracted from WT, TgGFP(-), and TgGFP(+) embryos were run on adjacent
194 lanes on an SDS-PAGE gel then the proteins were transferred to a membrane for Western
195 blotting using the RLC antibody. Intensities of the HCRLC-(PA)GFP and ZRLC bands were

196 converted to HCRLC-(PA)GFP and ZRLC amounts and combined into the replaced fraction,
197 ZRLC_{rep}, given by,

$$198 \quad ZRLC_{rep} = \frac{[HCRLC - GFP]}{[HCRLC - GFP] + [ZRLC]} \quad (1)$$

199 where [...] indicates mole protein and all bands came from the TgGFP(+) embryos.
200 Independently, the amount of ZRLC removed was measured relative to a β -actin loading
201 standard in WT and transgenic embryos and using the RLC and a β -actin antibody (1:2000
202 dilution, product number 4967, Cell Signaling Technology, Danvers, MA,) [14]. The ZRLC
203 fraction lost due to transgenesis, ZRLC_{rem}, is given by,

$$204 \quad ZRLC_{rem} = \frac{[ZRLC]_{WT} - [ZRLC]_{TgGFP(+)}}{[ZRLC]_{WT}} \quad (2)$$

205 Experiments were conducted at room temperature (20-22 °C).

206

207 **Single cardiac myosin imaging in a beating heart.**

208 At 3-4 dpf, TgGFP(+) embryos were imaged to detect single cardiac myosin dynamics in
209 the ventriculum. A TgGFP(+) embryo was placed in a 200 μ m deep microfluidic channel
210 constructed from polydimethylsiloxane (PDMS) with the channel side up and immersed in 20 μ L
211 of 30% Danieau Buffer (D-buffer, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO₄, 0.18 mM
212 Ca(NO₃)₂, 1.5 mM HEPES, pH 7.6). We introduced stepwise concentrations of tricaine, up to
213 2000 mg/L, to reduce heart rate from 108-125 bpm to 50-60 bpm at 20 °C to facilitate single
214 myosin imaging. Heart rate returned to normal immediately after flushing out the drug with fresh
215 buffer and the drug cleared naturally from the embryo at \geq 10 minutes. Heart rate was monitored
216 in a stereo microscope at high magnification. When heart rate stabilized the bathing solution
217 volume was drawn down to $<$ 6 μ L and the microfluidic was inverted then placed on top of a #0
218 glass coverslip forming a water tight seal with the glass for imaging exactly as described [10].
219 Embryos were imaged over time at a 10 Hz frame rate to collect single molecule emission
220 images from photoactivated RLC-PAGFP. Imaging sessions were completed within 10 min.

221 Heart rate was measured visually in the microscope every 2-3 min and remained constant at 50-
222 60 bpm over the course of the experiment. Blood circulation in capillaries in the fish tail was also
223 monitored every 2-3 min in the microscope by visualizing blood cell movement. Blood cell flow
224 did not qualitatively change over the course of the experiment.

225 We briefly stopped the heart by raising tricaine to 2200 mg/l in the microfluidic
226 containing the embryo then imaged the constantly-relaxed cardiac myosin.

227

228 **B. *In Vivo* single myosin orientation quantitation**

229 **S1/GFP coordination and coordinates.**

230 The ribbon structure in **Fig 1** shows the myosin heavy chain (MHC) in blue and black,
231 RLC and ELC binding the lever-arm in red and silver, and the GFP moiety in green. GFP is
232 linked to the RLC C-terminus by the white linker. The S1 structure represents human β -cardiac
233 myosin from homology modeling [15] of its sequence using the chicken skeletal myosin S1
234 crystal structure 2mys [16]. The arrow indicates direction of the black section of the lever-arm α -
235 helix symmetry axis where RLC binds. The GFP chromophore in the middle of the β -barrel is
236 indicated in red. The red arrow at the chromophore is the emission dipole orientation.

237

238

239

240 **Fig 1. The coordination of the GFP moiety (green) and its emission dipole moment (red**
241 **arrow) with myosin S1 consisting of a heavy chain (blue and black), ELC (silver), and RLC**
242 **(red).** The portion of the lever-arm in the heavy chain appearing in black is the α -helix segment
243 associated with the lever-arm orientation and depicted by the black arrow. The insert shows the
244 time-resolved coordinates for GFP chromophore emission dipole moment in red and lever-arm
245 helix in blue corresponding to spherical polar angles (β', α') and (β, α) defined relative to a fiber
246 fixed frame.

247

248

249

250 The insert has a blue arrow with embedded black α -helix representing the lever-arm with
251 coordinates (β, α) defined relative to the unique fiber symmetry axis (z) and arbitrary x -axis
252 defining the fiber frame. The red arrow with embedded chromophore moiety represents the GFP
253 chromophore emission dipole related to the lab frame by (β', α') and referred to as probe
254 coordinates.

255 The fiber frame xz plane in **Fig 1** lies in the microscope focal plane and in the lab frame
256 as shown in **Fig 2**. Lab and fiber frames are related to each other by a rotation through χ about
257 the y -axis (y -axis not shown). Images of the heart shown in Results relate to the lab frame like
258 the test pattern in **Fig 2**.

259

260

261 **Fig 2. The fiber frame xz plane in Fig 1 lies in the microscope focal plane and in the lab**
262 **frame as shown.** Lab and fiber frames are related to each other by a rotation through χ . Images
263 of the heart shown subsequently relate to the lab frame like the image of the test pattern.

264

265

266

267 **Orientation super-resolution measured from tagged zebrafish muscle.**

268 Zebrafish embryos confined to the microfluidic chamber were imaged with fluorescence
269 from the cardiac tissue as described above. Single molecule fluorescence measurements from the
270 photoactivated HCRLC-PAGFP tagged myosin lever-arms were made on an inverted microscope
271 using highly inclined thin illumination (HILO) excitation exactly as described [10].

272 In all fluorescence experiments, pump and observation exciting laser light polarization is
273 p-polarized and propagating perpendicular to the long dimension of the embryo. In the heart
274 tissue the fiber symmetry axis is not fixed but redefined for each single myosin. A sparse
275 population of probes is photoactivated to achieve the most selective orientation distribution of
276 photoactivated probes by using the lowest practical pump beam intensity. We identified single
277 molecule events by their quantized intensity change due to photoactivation or photobleaching
278 over time. Orientation super-resolution of unit vector $\mu_e[A]$, the *emission* dipole moment of the
279 activated single molecule, is determined by pattern recognition exactly as described [10].

280 Raw GFP fluorescence intensity vs time from RLC-PAGFP tagged myosin *in vivo* from
281 beating and relaxed zebrafish embryo heart ventriculum under HILO illumination is shown in
282 **Figs A & B** in S1 File. Single myosins are identified by their quantized intensity change of ~1000
283 photons per 0.1 second above background due to photoactivation and subsequent photobleaching
284 to background. Photon counts indicate intensity integrated over the EMCCD camera 11x11 pixel
285 array containing the photoactivated chromophore image. Video files for these single myosin
286 instances are in S1-S4 Movies.

287

288 **S1/GFP coordination.**

289 The S1/GFP coordination of the zebrafish skeletal muscle was determined as described
290 [10] and is shown in **Fig 1**. For the present study and using the same method, we checked the
291 new dipole orientation data for relaxed and contracting muscle (summarized subsequently in
292 RESULTS) for consistency with the S1/GFP coordination in **Fig 1**. We found that the new data
293 is consistent with the previous data in selecting the S1/GFP coordination in **Fig 1** over other
294 docked models.

295

296 **In vivo step-size.**

297 Single molecule images provided super-resolved orientation of the photoactivated RLC-
298 PAGFP emission dipole in zebrafish cardiac muscle. Dipole orientations were computed from

299 images that were continuously recorded for 20-40 sec. Object spatial drift, if present, was
300 removed by large frame image alignment prior to analysis. The time-resolved coordinates have
301 dipole or lever-arm helix spherical polar angles (β', α') or (β, α) defined relative to a fiber fixed
302 frame shown in the insert to **Fig 1**. They are the trajectories for a single dipole or lever-arm helix.

303 The arc subtended by, Φ , the angle a single lever-arm helix rotates in sequential time-
304 correlated images defines a sequence of chords on a circle of diameter L equal to the lever-arm
305 length indicated in **Fig 3**. Chord length is step-size, d , given by,

$$306 \quad d = 2L \sin\left(\frac{1}{2}\Phi\right) \quad (3)$$

307 Step-sizes computed by eq. 3 from many single myosin trajectories are summarized as a
308 histogram of incremental step-lengths vs the number of observed events. Step-lengths distribute
309 differently for various muscle physiological states. Cardiac muscle contraction separates into
310 auxotonic and isometric phases depending on position in the heart beat cycle with the auxotonic
311 phase early in systole when fibers are shortening but overall muscle position is relatively steady.
312 Towards the end of systole, fiber shortening slows as force reaches isometric level and the
313 muscle image sharpens to its peak S/N ratio.

314

315

316

317 **Fig 3. Myosin S1 consisting of a heavy chain, ELC (blue), and RLC (yellow) performing a**
318 **powerstroke with a lever-arm rotation while strongly actin bound.** The arc subtended by, Φ ,
319 the angle a single lever-arm helix rotates in sequential images defines a sequence of chords on a
320 circle of diameter L equal to the lever-arm length indicated. Chord length is step-size, d , given by
321 eq. 3. The ELC N-terminal extension, shown actin bound at the end of the powerstroke, plays a
322 major role in the proposed mechanism for strain sensing in the myosin.

323

324

325

326 During contraction muscle has single myosins cycling through lever-arm orientations for
327 actin-disassociated (relaxed) and actin-associated (force generating) conformations. The
328 relaxation phase in diastole is not identified in the beating heart cycle because the muscle
329 translates sufficiently to leave focus. The relaxed phase is observed separately in the heart when
330 its beat cycle is briefly interrupted by additional tricaine. Relaxed phase muscle has single
331 myosins maintaining a mostly actin-dissociated form with statically and dynamically averaged
332 lever-arm orientation that is non-stationary in its time sequence over sampling intervals of 100
333 ms. Myosin develops force with its lever-arm swing starting in the high free-energy actin bound
334 state of the myosin most closely associated with auxotonic phase. Peak force has myosin
335 strongly actin-bound either with ADP or after ADP release (strained rigor) most closely
336 associated with isometric phase. Both force generating phases also contain contributions from
337 detached (relaxed) myosins and their active counterpart (isometric with auxotonic phase or
338 auxotonic with isometric phase) due to asynchronous myosin cycling.

339 We model the step-size distribution in auxotonic and isometric phases of the heartbeat,
340 v_{au} and v_{is} , with linear combination of distributions composed of relaxed, v_{re} , and alternatively v_{is}
341 and Δv_{au} for the auxotonic case or v_{au} and Δv_{is} for the isometric case, where Δv_{au} and Δv_{is} are
342 unknown force developing homogeneous auxotonic and isometric phases of the heartbeat,
343 subject to constraints,

$$\begin{aligned} \Delta v_{au} &= v_{au} - c_1 v_{is} - c_2 v_{re} \\ \Delta v_{is} &= v_{is} - c_3 v_{au} - c_4 v_{re} \end{aligned} \tag{4}$$

345 for unknown constants c_j , $j = 1, 2, 3$, and 4. The relaxed and active step-size histograms, v_{re} , v_{is} ,
346 and v_{au} are the basis vectors covering probability space spanned by tagged lever-arm
347 orientations. They have Poisson distributed noise randomly sampled while Δv_{is} and Δv_{au} are
348 independently minimized for each trial by selection of c_j subject to constraints Δv_{au} , Δv_{is} , and c_j
349 all ≥ 0 using constrained linear programming in Mathematica. We estimate the mean and variance
350 for Δv_{is} and Δv_{au} at each point in the histogram from the family of residuals produced in the
351 trials.

352

353 **Pathway networks.**

354 Qdot assaying of porcine β -ventricular myosin (β mys) indicated three unitary steps-sizes
355 of ~ 3 , ~ 5 , and ~ 8 nm with relative step frequencies of ~ 13 , 50, and 37% [17]. Similar results
356 were obtained using the assay for adult zebrafish skeletal myosin step-size and step-frequency
357 [11]. We proposed that the major 5 nm step is the default step identical to the dominant step in
358 skeletal myosin [18], that the 8 nm step is somewhat less likely and different from the 5 nm step
359 by involving an extra interaction with actin via the unique N-terminus extension of ELC [4, 19-
360 21], and that the minor 3 nm step is the unlikely conversion of the 5 nm step to the full cELC
361 bound 8 nm step. The 3 nm step is isolated in time from the 5 nm step by slow ADP dissociation
362 hence we sometimes observe it as a separate step [22]. We tested the N-terminus of ELC for its
363 ability to regulate step-size and/or step-frequency using β mys and mouse cardiac myosin with
364 the α heavy chain (α mys) including: a 17 residue N-terminal truncated ELC in porcine
365 ventricular myosin made by papain digestion [23] and a 43 residue N-terminal truncated human
366 ELC expressed in a transgenic mouse heart [24]. ELC N-terminus truncation caused significant
367 redistribution in the step-frequencies among the unitary steps compared to control. An ensemble
368 containing mainly myosin with ELC missing its N-terminus had significantly lower probability
369 for making the 8 nm step but higher probability for the 5 nm step in both porcine β mys mouse
370 α mys. ELC N-terminus truncation had little effect on the unitary myosin step-sizes [5].

371 The earlier in vitro work was described by a model where the 3 nm step happened only
372 after a 5 nm step occurred. Three pathways producing 5, 8, or 5+3 nm steps describe this 3-
373 pathway network. The present in vivo work implies that the 3 nm step can also occur
374 independently from the 5 nm step because we observe a 3 nm step-frequency that sometimes
375 exceeds that for 5 nm step. Four pathways producing 5, 8, 5+3, and 3 nm steps describe the new
376 4-pathway network that is the basis for the new model discussed in RESULTS. The 4-pathway
377 network is a superset of the 3-pathway network.

378

379 **Relaxed myosin lever-arm orientation dynamics.**

380 Relaxed myosin dimers in the cardiac thick filament form intra- and inter-dimer
381 interactions thought to impact the in vivo muscle. Isolated myosin dimers exhibit the intra-dimer
382 blocked and free head motif [25] within the hierarchical quasihelical thick filament structure
383 [26]. The latter grants inter-dimer interactions stabilizing a globally regular but locally variable
384 myosin 3D structure. Static variability is probably accompanied by dynamic dispersion as
385 myosin monomers sample conformation space. We hypothesize that single myosin head
386 dynamics observed in the relaxed zebrafish cardiac muscle results from the conformation space
387 sampling. We estimate potential effects of conformation space sampling by using the tarantula
388 myosin filament reconstruction (3jbh.pdb) as a model for relaxed cardiac muscle [27]. Single
389 myosin measurements track lever-arm orientation relative to the thick filament axis using a
390 specific region of the lever-arm helix equivalent to the black section of the human cardiac
391 myosin lever arm in **Fig 1** (residues 808-827, tarantula sequence) that we estimate for the
392 tarantula myosin. Thick filament axis orientation is estimated using a specific region of S2
393 (residues 943-962, tarantula sequence). Thick filament axis orientation computed from each of
394 the 4 myosins in the tarantula structure estimates a probability density for variability in thick
395 filament structure that we assume single myosins sample during the course of the time-resolved
396 lever-arm orientation measurement. We estimate the relaxed lever-arm step-size by computing Φ
397 for lever-arm orientation relative to random variates of the thick filament structure substituting
398 for a time-dependent trajectory. Φ 's are converted to step-size using eq. 3 and giving a step-size
399 histogram comparable to observation.

400

401 **Results**

402 **HCRLC-GFP stoichiometry in the zebrafish heart.**

403 We detected the ZRLC and HCRLC-GFP protein content in WT and TgGFP(+) embryo
404 and adult zebrafish hearts using SDS-PAGE and combining Sypro Ruby staining and
405 immunoblotting for detection of protein content. **Fig 4** shows the Sypro Ruby stained and
406 immunoblotted SDS-PAGE gels. The Sypro Ruby gel band intensities establish ZRLC content in
407 a zebrafish adult heart extract relative to a known amount of in vitro expressed HCRLC (**panel**
408 **a**). These samples produce calibrated blot intensities for HCRLC and ZRLC under a standardized
409 protein immunoblotting protocol using the RLC antibody as described in Methods and
410 previously [11]. The standards are compared to immunoblots from HCRLC-GFP and ZRLC in
411 WT and TgGFP(+) embryos (**panel b**) to measure relative fractions of HCRLC-GFP and ZRLC
412 content ($ZRLC_{rep}$, eq. 1). The relative amount of ZRLC in WT and TgGFP(+) embryo hearts
413 confirmed ZRLC content removed ($ZRLC_{rem}$, eq. 2) by their comparison to control β -actin
414 expression (**panel c**) as described in Methods and previously [11]. Results agree that $ZRLC_{rep} =$
415 0.63 ± 0.04 where error is standard deviation for $n=6$. Each sample size has ~ 80 embryos.

416

417

418

419 **Fig 4. The Sypro Ruby stained and immunoblotted SDS-PAGE gels. The Sypro Ruby gel**
420 **band intensities establish ZRLC content in a zebrafish adult heart extract relative to a**
421 **known amount of in vitro expressed HCRLC (panel a).** These samples produce calibrated blot
422 intensities for HCRLC and ZRLC under a standardized protein immunoblotting protocol using
423 the RLC antibody as described in Methods and previously [11]. The standards are compared to
424 immunoblots from HCRLC-GFP and ZRLC in WT and TgGFP(+) embryos (**panel b**) to
425 measure relative fractions of HCRLC-GFP and ZRLC content ($ZRLC_{rep}$, eq. 1). The relative
426 amount of ZRLC in WT and TgGFP(+) embryo hearts confirmed ZRLC content removed
427 ($ZRLC_{rem}$, eq. 2) by their comparison to control β -actin expression (**panel c**).

428

429

430

431 **Effect of HCRLC-GFP on zebrafish embryo heart contractility.**

432 **Fig 5** compares heart rate in beats per minute (BPM), shortening fraction (SF), and
433 cyclical ventricle volume changes for WT and TgGFP(+) embryos in the presence (blue) and
434 absence (black) of PTU. Error bars show standard deviation for *n* embryos. HCRLC-GFP
435 incorporation into ~60% of the cardiac myosins in the heart has no significant impact on
436 performance measured with these metrics. The PTU treatment inhibits melanogenesis and
437 improves contrast in embryo heart images. It likewise has no significant impact on these metrics.

438

439

440

441 **Fig 5. Comparison of heart rate in beats per minute (BPM), shortening fraction (SF), and**
442 **cyclical ventricle volume changes for WT and TgGFP(+) embryos in the presence (blue)**
443 **and absence (black) of PTU treatment.** Error bars show standard deviation for *n* embryos.

444

445

446

447 **Quantitation of embryonic zebrafish cardiac myosin lever-arm swing during**
448 **the heart beat cycle.** At 3-4 dpf, TgGFP(+) embryos were imaged to detect single cardiac
449 myosin dynamics in the ventriculum as described in METHODS. **Fig 6** shows a single frame
450 from a movie and the averaged image of the beating heart where single molecule candidates are
451 visible. This movie records ~6 sequential in-focus images of the sarcomeres followed by ~4
452 blurred images of shortening or otherwise moving sarcomeres and muscle fibers. In-focus

453 images show approximately isovolumetric contraction since muscle shortening follows. We
454 observed that the S/N ratio of the single myosin fluorescence is largest at highest isometric force
455 just before ejection. We use this feature to synchronize the cardiac cycle with fluorescence
456 intensity. The 1-2 highest S/N images were used for quantitation of the near-isometric
457 contraction phase. The remaining 4-5 in-focus images were used for quantitation of the
458 auxotonic contraction phase. We also stopped the heart by raising tricaine to 2200 mg/l in the
459 microfluidic containing the embryo then briefly imaged the constantly-relaxed cardiac myosin.

460

461

462

463 **Fig 6. A single frame (left) and an averaged image of the heart (right) running at 50-60**
464 **bpm.**

465

466

467

468 Single myosin candidate images are isolated into 11x11 pixel movies from which the
469 total intensity of each frame is plotted over time. From the intensity vs time plots we identify the
470 single molecule photoactivation and photobleaching events thus qualifying the single myosin
471 movie for inclusion into the data set. **Figs A & B** in S1 File indicate intensity vs time plots for
472 single myosins in active and relaxed cardiac muscle.

473 The single molecule intensity patterns from zebrafish embryo single cardiac myosins
474 were fitted using the pattern recognition algorithm and subjected to orientation super-resolution
475 analysis [28, 29]. Time-resolved coordinates, having dipole or lever-arm helix spherical polar
476 angles (β', α') or (β, α) defined relative to a fiber fixed frame (**Fig 1**), indicate the trajectories for
477 a single dipole or lever-arm. Dipole orientation data impacts the best choice for the S1/GFP
478 coordination. The new data representing cardiac myosin in relaxed and active muscle is
479 consistent with the previous data selecting the S1/GFP coordination in **Fig 1** over other docked

480 models [10, 11]. The arc subtended by, Φ , the angle a single lever-arm helix rotates in sequential
481 images defines a sequence of chords on a circle of diameter L equal to the lever-arm length
482 indicated in **Fig 3**. Chord length is step-size, d , given by eq. 3.

483 We modeled the force developing homogeneous auxotonic and isometric phases, Δv_{au}
484 and Δv_{is} using eq. 4 and as described there. Known relaxed and active step-size histograms v_{re} ,
485 v_{au} , and v_{is} are assigned their Poisson distributed noise and randomly sampled while Δv_{au} or Δv_{is}
486 are minimized for each trial by selection of c_1 and c_2 or c_3 and c_4 subject to constraints $c_1, c_2, c_3,$
487 $c_4, \Delta v_{\text{au}}$, and Δv_{is} all ≥ 0 using constrained linear programming. We estimate average and variance
488 for Δv_{au} and Δv_{is} from the trials. Standard deviation of the mean for Δv_{au} or Δv_{is} is computed for
489 15 or 24 cardiac muscle fibers from 8 or 6 embryos and corresponding to 1251 or 1436 single
490 myosin coordinates from relaxed and active hearts, respectively.

491 **Fig 7 panels a-c** display the cardiac myosin cycle from homogeneous auxotonic (Δv_{au}),
492 through homogeneous near-isometric (Δv_{is}), to relaxation (v_{re}). **Fig 7 panel d** compares in vivo
493 skeletal myosin step-size in relaxation from zebrafish embryo trunk muscle [11] with the cardiac
494 data. The skeletal (red) contrasts with the cardiac relaxed muscle (black) from the present study
495 (**panels c or d**) where the relaxed cardiac myosins occupy a 2x larger step-size domain. The
496 difference could be due to the higher time-resolution in the cardiac measurement or to other
497 factors distinguishing cardiac and skeletal myosin. The former could convert a stationary relaxed
498 lever-arm orientation observed from the in vivo skeletal myosin time-resolved trajectory into the
499 non-stationary one observed for the in vivo cardiac myosin provided dynamic/static myosin
500 rotational relaxation time was poised between 100 and 1000 ms. This is unlikely because rotation
501 relaxation of the myosin head in relaxed skeletal muscle is on the order of 300-1000 ns [30].
502 Considering the latter, inter- and intra-myosin dimer interactions are known to impact relaxed
503 myosin structure in cardiac thick filament [26] possibly leading to the more widely statically and
504 dynamically distributed relaxed lever-arm [27]. We simulated the potential effect of thick
505 filament interactions on relaxed cardiac myosin apparent step-size using the tarantula skeletal
506 muscle thick filament structure as a model [27] and the approach described in METHODS. **Fig 7**
507 **panel d** compares simulated (blue) and observed relaxed myosin step-size distributions from
508 cardiac (black and same as in **panel c**) and skeletal (red) zebrafish embryo muscle. Agreement
509 between the cardiac muscle and simulated curves implies that inter- and intra-myosin dimer

510 interactions impacting relaxed myosin structure in cardiac thick filament could explain the larger
511 apparent step-size domain compared to the zebrafish skeletal muscle. While thick filament
512 dispersion is likely also manifest in the skeletal muscle, our data suggests cardiac muscle myosin
513 is dynamically distributed more widely on the 100 ms time scale.

514

515

516

517 **Fig 7. Panels a-c. In vivo cardiac myosin active cycle from auxotonic (force developing),**
518 **through near-isometric (maximum force), to detachment (relaxation) phases.** Error bars
519 indicate standard deviation of the mean for 15 or 24 cardiac muscle fibers from 8 or 6 embryos
520 and corresponding to 1251 or 1436 single photoactivated myosin coordinates from relaxed and
521 active hearts, respectively. Dotted vertical lines in panels **a & b** define the boundaries between
522 step-size frequencies computed from areas under the curves for nominal steps of 0, 3, 5, and 8
523 nm (nominal step-size corresponds to the in vivo measured step-sizes of 0, 2, 4, and 6 nm as
524 indicated on the x-axis legend). Areas at step-size boundaries are split equally between adjoining
525 step-sizes. **Panel d.** Simulated (blue) and observed (black and same as in **panel c**) relaxed
526 cardiac (ca) myosin step-size distribution. Simulation is based on dispersion of thick filament
527 structure surmised from the atomic model of Alamo et al. [27] as described in METHODS. In
528 vivo relaxed skeletal (sk) myosin step-size from zebrafish embryo trunk muscle (red) is shown
529 for comparison [31].

530

531

532

533 Time-resolved single molecule experiments follow myosin through its cycle in real time.
534 These data are summarized with event/step-size histograms also indicating step-frequency for the
535 three unitary step-sizes observed. In vivo step-size from homogeneous auxotonic and near-
536 isometric cardiac myosin in **Fig 7 panels a & b** indicates step-size probabilities peaking at ~2, 4

537 and 6 nm paralleling the unloaded in vitro estimates of ~3, 5, and 8 for zebrafish skeletal myosin
538 [11]. Strain in the active cardiac myosin under load probably affects the apparent in vivo step-
539 sizes by compacting the lever-arm rotation angle Φ . **Fig 7 panel b** indicates a force bearing 0
540 length step-size in the near-isometric phase that is unique to the in vivo myosin.

541

542 **Contraction cycle 4-pathway model.**

543 **Fig 8** indicates a 4-pathway network producing 3, 5, and 8 nm steps (2, 4, and 6 nm in
544 vivo) over the in vivo myosin cycle. Actin weakly attached states fall outside the dashed green
545 box. Quantities f_i are myosin flux through the cycle with green and black indicating observed
546 and computed values. We have shown previously using the Qdot assay that the basis of the 3, 5
547 and 8 nm unitary steps is the actin binding of the ELC N-terminus in a mechanism summarized
548 in the figure [5]. Ignoring for a moment the shaded regions containing hypothetical strain
549 dependent states, the bottom pathway with flux f_4 performs the 5 nm step with release of product
550 (Pi followed by ADP) but without attachment of the ELC N-terminus then ATP binding and
551 actin detachment (f_5). Alternatively, following a 5 nm step, slow ADP dissociation allows the
552 ELC N-terminus to occasionally bind actin to make a subsequent 3 nm step with ADP release
553 (f_7) then ATP binding and actin detachment. The top pathway (f_1) performs the 8 nm step with
554 product release (Pi followed by ADP) and attachment of the ELC N-terminus then ATP binding
555 and actin detachment. Pathways just described were identified previously in the context of the
556 Qdot assay [5]. The middle pathway has flux f_3 and a 3 nm step not preceded by a 5 nm step. It
557 has Pi release without strong actin binding to avoid a 5 nm step, followed by ADP bound myosin
558 strong actin attachment, then the 3 nm displacement. It is populated when actin has sufficient
559 resisting force explaining its absence from the unloaded Qdot assay experiments. It is needed to
560 accommodate the real situation when the quantity of 3 nm steps exceeds that of 5 nm steps. For
561 each myosin state, blue vector \mathbf{v} at the end of the myosin lever-arm is positive net force on, and
562 positive velocity of, the thick filament in units where amplitudes are equal.

563

564

565

566 **Fig 8. Myosin flux through the 4-pathway network contrasting 3 phases of muscle**

567 **contraction in the beating heart.** Myosin begins and ends detached from actin and with ATP
568 bound in the contraction cycle. The green box with dashed line boundaries group the strong
569 actomyosin bound states. Blue vector \mathbf{v} at the end of the myosin lever-arm is positive net force
570 on, and positive velocity of, the thick filament in units where amplitudes are equal. Fluxes
571 through the network, f_i , differ depending on contraction phases (values in **Table 1**). Measured
572 values for f_i are in green while computed values are indicated in black. Four pathways cross from
573 beginning to end of the contraction cycle. The top pathway populated by flux f_1 executes an 8 nm
574 step-size. The middle pathway populated by flux f_3 executes a 3 nm step-size. It releases Pi while
575 weakly actin bound without doing work. The bottom pathway populated by flux f_4 is branched
576 and executes 5 or 5+3 nm step-sizes. The branch from the bottom pathway is populated by flux f_7
577 and executes the 5+3 nm step-size. Strain sensitivity is modeled with mechanisms in two
578 subpathways within the shaded regions. The upper mechanism is populated by fluxes f_2 and f_8
579 from the 8 and 3 nm steps when the ELC N-terminus binds actin for actomyosin in rigor. The
580 taut (blue line), intermediate (green curve), and slack (red wave) ELC N-terminus for muscle in
581 near-isometric, auxotonic, or unloaded phases have high, modest, or zero strain when net force \mathbf{v}
582 is zero in isometric, intermediate in auxotonic, or high in unloaded phase. The linear (blue) actin
583 bound ELC N-terminus is proposed to inhibit ATP binding by lowering active site accessibility
584 for ATP at the small arrow near the myosin head. Inhibited ATP binding extends actomyosin
585 attachment time indicated by the clock icon and quantitated in our single myosin measurements
586 as a 0 length step. The lower mechanism is populated by flux f_6 from the 5 nm step with ADP
587 bound. Near-isometric, auxotonic, or unloaded phases have high, intermediate, or zero strain (of
588 an unspecified myosin element) when net force is zero, intermediate, or high. Strain lowers ADP
589 release rate. Short duration ADP rate inhibition flux, f_7 , leaves to continue with the 3 nm step.
590 Long duration ADP rate inhibition flux, $f_6 - f_7$, continues with the 0 length step. For either the
591 ATP accessibility or ADP release rate mediated mechanisms (top or bottom strain sensing
592 mechanisms), low net force inhibits myosin cycling by extending the time myosin is strongly
593 actin bound by $>2\Delta t$.

594

595

596

597 Shaded regions in **Fig 8** contain models for long lived strained conformation states in two
598 mechanisms. The upper mechanism is populated by fluxes f_2 and f_8 from the 8 and 3 nm steps
599 when the ELC N-terminus binds actin and the myosin is in rigor. The taut (blue) versus slack
600 (red) ELC N-terminus in near-isometric versus unloaded phases have high versus zero strain
601 when net force (or velocity) is zero in isometric contraction versus $\gg 0$ in unloaded conditions.
602 Taut ELC N-terminus is proposed to strain myosin in rigor (strained rigor) inhibiting ATP
603 binding by lowering active site ATP accessibility as indicated by the size of the opening at the
604 arrow near the myosin head. Delayed ATP binding and detachment (for $>2\Delta t$) gives a state
605 observed as the force bearing 0 length step (f_2 or f_8). Slack ELC N-terminus has only prompt
606 ATP binding and actin detachment ($f_2 = f_8 = 0$). The lower mechanism is populated by flux f_6
607 from ADP bound myosins. Near-isometric versus unloaded phases have high versus zero strain
608 when net force (or velocity) is zero in isometric contraction versus $\gg 0$ in unloaded conditions.
609 ADP release rate is diminished in the former case. Spontaneously slow ADP release that is not
610 caused by strain allows additional time ($\sim\Delta t$) for the ELC N-terminus to bind actin and perform a
611 3 nm step. Flux f_7 follows this pathway. The remainder has delayed ADP release caused by strain
612 (for $>\Delta t$) giving a state observed as a 0 length step. Unloaded conditions without strain have $f_6 =$
613 0 with prompt ATP binding and actin detachment (f_5) or a subsequent 3 nm step (f_7). For either
614 mechanism, the net effect of high strain is to inhibit myosin cycling by extending the time by
615 $>2\Delta t$ that myosin is strongly actin bound giving the 0 length step state with a summed flux, $f_9 =$
616 $f_2 + f_6 - f_7 + f_8$, measured by the data in **Fig 7**.

617 The force bearing 0 length step-size involves a temporary diversion of myosin flux into
618 an inhibited state that does not provide a parallel pathway through the myosin active cycle.
619 Traditional normalization has step-frequencies for the 3, 5, and 8 nm steps summing to 1 such
620 that,

621
$$x_0 = \frac{\omega_0}{1-\omega_0}, \quad x_3 = \frac{1-(\omega_0+\omega_5+\omega_8)}{1-\omega_0}, \quad x_5 = \frac{\omega_5}{1-\omega_0}, \quad \text{and} \quad x_8 = \frac{\omega_8}{1-\omega_0} \quad (5)$$

622 where ω_0 , ω_3 , ω_5 , and ω_8 are areas under the probability curves for the ~0, 3, 5, and 8 nm step-
623 sizes indicated in **Fig 7 panels a & b**. Flux values for all phases studied are summarized in
624 **Table 1**. The caption provides additional details about quantitation of ω_0 , ω_3 , ω_5 , and ω_8 from
625 **Fig 7** and the optimization routine to obtain fluxes not directly observed.

626

627

628 **Table 1**^a. Cardiac myosin flux through *in vivo* active cycle in 3 phases.

| | | Step-probability | | | | | | | | |
|---------------------|----------------------|------------------|------------|------------|---------------------|------------|------------------|---------------|---------------|---------------------|
| phase | ω_0 | ω_3 | ω_5 | ω_8 | | | | | | |
| Unloaded (n=27) | 0 | 0.13±0.04 | 0.50±0.09 | 0.37±0.08 | | | | | | |
| Auxotonic (24) | 0.03±0.12 | 0.44±0.27 | 0.45±0.17 | 0.08±0.04 | | | | | | |
| Near-isometric (24) | 0.33±0.02 | 0.54±0.04 | 0.12±0.03 | 0.01±0.01 | | | | | | |
| | | | | | | | | | | |
| | | Flux | | | | | | | | |
| phase | f_1 | f_2 | f_3 | f_4 | f_5 | f_6 | f_7 | f_8 | f_9 | f_{10} |
| Unloaded | 39±7 | 0 | 5±8 | 56±9 | 43±11 | 13±9 | 13±9 | 0 | 0 | 18±12 |
| Auxotonic | 10±5 | 2±1 | 31±23 | 59±23 | 37±21 | 29±11 | 21±9 | 3±4 | 13±11 | 52±22 |
| Near-isometric | 2±1 | 1±1 | 80±5 | 18±5 | 12±3 | 15±4 | 6±2 | 42±5 | 52±4 | 86±3 |
| notes | input & output | $\leq f_1$ | input | input | output f_4-f_7 | $\leq f_5$ | 5→3 f_4-f_5 | $\leq f_{10}$ | $f_2+f_6+f_8$ | output f_3+f_7 |

629 ^a **Table 1** (top) has step-probabilities measured from the data in **Fig 7 panels a & b** for 0, 3, 5,

630 and 8 nm steps (0, 2, 4, and 6 nm in vivo) computed from areas under the probability curves and
631 for auxotonic and isometric phases. Areas are defined in the figure panels by the vertical dotted
632 lines with probability at the step-size boundaries split equally between adjoining areas. Data for
633 the unloaded phase is taken from earlier in vitro work on porcine ventricular myosin (MYH7) [5,
634 17]. Step-probabilities $\{\omega_0, \omega_3, \omega_5, \omega_8\}$ are normalized to sum to 1. Errors are standard deviation
635 for (n) replicates. **Table 1** (bottom) has flux quantities, f_i , for the 4 step-size network defined in
636 the **Fig 8** model. Several flux values relate to known step-frequencies using eq. 5 and where $f_1 =$
637 x_8 , $f_4 = x_5$, $f_9 = x_0$, and $f_{10} = x_3$. Other fluxes are surmised by using constraints. Flux conservation
638 equality constraints include (total input) $f_1+f_3+f_4 = f_1+f_5+f_{10}$ (total output), $f_4 = f_5+f_7$ (5 nm step
639 input detaches or continues to 3 nm step), $f_3+f_7 = f_{10}$ (3 nm step input sums with 5/3 nm step
640 conversion then detaches with a 3 nm step), and $f_2+f_6 -f_7+f_8 = f_9$ (total 0 length steps). The
641 problem is under determined by equality constraints hence it is solved in two steps: first using
642 equality constraints eliminating 4 parameters, second using 3 equality constraints relating f_2 , f_3 ,
643 f_5 , f_6 , f_7 , and f_8 and inequality constraints for these variables. Inequality constraints are $f_2 \leq x_8$, f_2
644 $\leq x_0$, $f_3 \geq x_3-x_5$, $f_3 \leq x_3$, $f_5 \leq x_5$, $f_6 \leq x_5$, $f_7 \leq f_6$, $f_7 \leq x_5$, $f_8 \leq x_3$, $f_8 \leq x_0$, and all unknowns ≥ 0 . The
645 latter equality and inequality constraints are sufficiently restrictive to identify convergent
646 solutions for the fluxes for each phase using constrained linear programming in Mathematica. We
647 estimate standard deviations for fluxes within all constraints by generating random variates using
648 normal distributions for $\{\omega_0, \omega_3, \omega_5, \omega_8\}$, computing x_0 , x_3 , x_5 , and x_8 using eq. 5, then solving
649 for the unknown flux values. Flux errors are standard deviation for (n) replicates. Total input (or
650 equivalently total output) is re-normalized to 100% post hoc facilitating comparison between
651 phases.

652

653

654 Step-frequencies quantitate step-size probability but they are ambiguous in the 4-
655 pathway network since a particular myosin passing through its cycle could do 5 then 3, 5, or 3
656 nm steps. The relative fluxes through the 4 pathways in **Fig 8** are unique in this regard. **Table 2**
657 summarizes myosin 4-pathway flux for the beating zebrafish embryo heart. They accommodate

658 the new step-size generating model in which the 3 nm step has a dedicated input pathway in
 659 addition to the 3 nm step dependent on input to the 5 nm step.

660

661

662 **Table 2. Myosin flux through the 4-pathway network in a zebrafish embryo beating heart.**

| | step-size (in nm) ^a and normalized flux ^b | | | |
|------------------------------|-----------------------------------------------------------------|-------------|-------------|-------------|
| phase | 8 nm | 5 nm (only) | 3 nm (only) | 5 then 3 nm |
| Unloaded (n=27) ^c | 39±7 | 43±11 | 5±21 | 13±9 |
| Auxotonic (24) | 11±5 | 43±22 | 25±31 | 21±9 |
| Near-isometric (24) | 2±1 | 12±3 | 80±6 | 6±2 |

663 ^a Step-sizes in vivo are ~6, 4, and 2 nm.

664 ^b Fluxes reflect total input or output at 100% for each phase. Errors are standard deviation for (n)
 665 replicates.

666 ^c Data for the unloaded phase is taken from earlier in vitro work on porcine ventricular myosin
 667 (MYH7) [5, 17].

668

669

670 The unloaded phase in **Fig 8** occupies the earliest part of the force producing cycle when
 671 velocity and net force are positive and largest. We model it with characteristics from the
 672 unloaded in vitro assay and under the assumption that there are no 0 length steps ($f_0 = 0$). The
 673 ELC N-terminus is shown as a slack curve (red) indicating it does not undergo enhanced or
 674 prolonged strain for large velocity and net force ($v \gg 0$). Input flux separates 39/5/56 into the 8,
 675 3, and 5 nm step pathways (f_1 , f_3 , and f_4) where f_1 and f_4 are derived initially from the traditional
 676 step-frequency percentages (ω_8 and ω_5) of 37 and 50% then undergo input normalization to

677 accommodate unknown f_3 . A fraction of myosins completing the 5 nm step release ADP with the
678 attachment of the ELC N-terminus ($f_6 = f_7$) to perform a subsequent 3 nm step. These are joined
679 by the direct contribution (f_3) together giving 18% of the output flux f_{10} . The pure 5 nm step
680 output (f_5) contributes 43% and the 8 nm step (f_1) independently contributes 39% of the output
681 flux. Output flux is $f_1+f_5+f_{10} = 100\%$.

682 The auxotonic phase in **Fig 8** produces lower velocity and net force than the unloaded
683 phase. It is characterized directly from the in vivo step-size data (**Fig 7**). The total 0 length step
684 flux (f_9) is approximately equivalent to error (**Table 1**). The observation that few 0 length steps
685 occur in the auxotonic phase lends credibility to the assumption that the unloaded phase makes
686 no 0 length steps. The ELC N-terminus is shown as a nearly taut curve (green) representing
687 modestly enhanced or prolonged strain when velocity and net force are modestly positive ($v > 0$).
688 Input flux separates 10/31/59 into the 8, 3, and 5 nm step pathways (f_1 , f_3 , and f_4). The input flux
689 of the 5 nm step (f_4) is about equal to that in the unloaded phase but more of these myosins also
690 undergo the coupled 3 nm step (f_7). These are joined by the direct contribution (f_3) together
691 giving all of the output flux f_{10} . Thus the 3 nm step-size flux enjoys a ~3-fold increase over the
692 unloaded phase. The 8 nm step suffers a 4-fold reduction in flux from 39 to 10% (f_1) when
693 compared to the unloaded phase. The modest net force probably lowers ADP release rate
694 sufficiently to shift myosin flux into f_7 favoring the 3 nm step pathway over the terminal 5 nm
695 step pathway (f_5) but insufficiently to produce significant 0 length steps.

696 The near-isometric phase in **Fig 8** produces near zero velocity and net force. It is also
697 characterized directly from the in vivo step-size data (**Fig 7**). The 0 length step flux at 52% (f_9)
698 indicates that half of the cardiac myosins have inhibited detachment from actin due to strain. The
699 ELC N-terminus is shown as a taut curve (blue) representing strongly enhanced or prolonged
700 strain when velocity and net force are nearly zero ($v \approx 0$). Input flux separates 2/80/18 into the 8,
701 3, and 5 nm step pathways (f_1 , f_3 , and f_4). The terminal 5 nm step-size flux (f_5) is low with 3 out
702 of 4 myosins first undergoing strain dependent inhibition. The 3 nm step-size flux (f_{10}) accounts
703 for most myosins at 86%, a large increase over auxotonic phase, but in this case most myosins
704 (80%) arrive there by the direct route with f_3 . The 8 nm step-size flux at 2% (f_1) is negligible.
705 The zero net force is proposed to enhance or prolong ELC N-terminus strain in strained rigor to
706 inhibit ATP binding and strongly shift myosin flux (f_6 and f_8) to favor the 0 length step

707 pathways. High flux through the 3 nm step-size pathway implies it clears the backlog of high
708 free energy or tension producing myosins at near-isometric force as it can continue to move
709 myosins through the active cycle when the other step-size pathways cannot indicating how the
710 motor down shifts to smaller step-size pathways in the near-isometric phase.

711 Dominance of the 3 nm step in isometric contraction implies a deeper significance
712 because this step results from actin binding of the ELC N-terminus. It implies the ELC N-
713 terminus is the nanomotor ratchet that locks the myosin into a force bearing state (0 length step)
714 until there is additional forward movement from another motor in the ensemble or when loading
715 force decreases with the movement of blood such that the ratchet can release locked myosin to
716 complete its ATPase cycle.

717 **Discussion**

718 Myosin in striated muscle transduces ATP free energy into the mechanical work of
719 moving actin. It does so using cyclical rotary movement of the lever-arm/light-chain complex
720 linking motor generated torque to the myosin filament backbone. The linear actin displacement
721 due to lever-arm rotation defines the unitary myosin step-size. The essential in vitro myosin
722 structure/function paradigm is captured by its single molecule mechanical characteristics
723 measured using the Qdot assay characterizing motor step-size and step-frequency [32]. Muscle
724 myosin performance beyond the essential structure/function paradigm is influenced by self-
725 assembly and integration with other motors and proteins in the muscle sarcomere. The native
726 integrated myosin, with potential for hierarchical coordinated functionality and regulation
727 because of its structured environment, was investigated here with cardiac myosin in live
728 zebrafish. We developed tools to measure and interpret in vivo single cardiac myosin lever-arm
729 rotation in a beating heart and estimate the cardiac myosin step-size and step-frequency. These
730 metrics provide unprecedented insight into native cardiac myosin structure/function.

731 Myosin unitary step-size and rotation (tilt) has been studied for a long time. Ensemble
732 myosin techniques used active muscle quick release or quick stretch length transients followed
733 by time-resolved measurements of force [33], myosin polarized fluorescence [34-36], and X-ray
734 diffraction [37] to compute the average unitary step-size or tilt under various loads. Later,
735 because of the laser trap [38], in vitro single myosin step-size measurements became a standard
736 and loaded myosin had a single, shorter, step-size [39]. Interest remained in ensemble force and
737 X-ray methods because they worked on live excised tissue where average step-size was likewise
738 shown to shorten with load. With transgenic zebrafish and the activatable tag on myosin,
739 measuring in vivo single myosin step-size is now possible as we report here. Although our work
740 on in vivo cardiac myosin extends our in vitro work where we identified the 3 unitary step-sizes
741 and their step-frequencies [17], there is also overlap and general agreement with the ensemble
742 average step-size measurements indicating a shorter average step with higher load. Comparing
743 ensemble average and single myosin results we find there are three critical distinctions. We
744 report that the average step-size shortens under increasing load due to shifting frequencies
745 among short, intermediate, and long unitary step-sizes, we directly observe the force bearing 0
746 length step, and the mechanism for how all of it is accomplished involving ELC N-terminus actin

747 binding follows directly from earlier in vitro single myosin measurements [5, 17]. The latter
748 indicates that shifting step-frequencies to favor the short step is a downshifting maneuver caused
749 by the ratcheting effect of the actin bound ELC N-terminus also showing that the in vitro and in
750 vivo systems closely correlate.

751 **Fig 7 panel d** contrast in vivo relaxed cardiac and skeletal myosin apparent step-size
752 probabilities indicating a more orientationally dynamically dispersed native cardiac myosin
753 lever-arm. Cardiac myosin is known to maintain various special conformations in relaxation
754 related to a super-relaxation state [26, 40-42] and the effect of RLC phosphorylation [43]. These
755 circumstances could impact relaxed myosin conformational sampling. We modeled this effect
756 using the structural heterogeneity indicated in an atomic model reconstruction for tarantula
757 myosin filament [27] and estimated relaxed lever-arm apparent step-size by computing Φ for
758 random variates of the thick filament structure substituting for a time-dependent trajectory. Φ 's
759 are converted to step-size using eq. 3 giving a pseudotime-dependent single myosin signal that
760 compares favorably to observation as indicated in **Fig 7 panel d**. While divergence of in vivo
761 lever-arm time-dependent trajectories in cardiac and skeletal muscle could be from the higher
762 time-resolution in the new cardiac measurement, earlier work with relaxed porcine cardiac
763 ventricular myosin lever-arm orientation from permeabilized papillary muscle fibers indicated a
764 similar pattern when compared to skeletal muscle at equivalent time resolutions [10]. We
765 conclude that the divergence of in vivo cardiac and skeletal observations on relaxed muscle
766 relates to the special conformations of cardiac thick filament.

767 Myosin translates actin when the two proteins are strongly bound. In the Qdot assay,
768 unitary actomyosin interactions are characterized in vitro with super-resolution microscopy [17].
769 Qdot assaying of porcine β -ventricular myosin (β mys) indicated three unitary steps-sizes of ~3,
770 5, and 8 nm with relative step frequencies of ~13, 50, and 37% [17]. Similar results were
771 obtained using the assay for adult zebrafish skeletal myosin step-size and step-frequency [11].
772 ELC N-terminus binding to actin is the mechanism for generating the 3 unitary steps [5] that is
773 modeled in a 4-pathway network in **Fig 8**.

774 In vivo step-size and step-frequency from auxotonic and near-isometric cardiac myosin in
775 **Fig 7 panels a & b** indicates step-sizes of ~2, 4 and 6 nm paralleling the unloaded in vitro

776 estimates of ~3, 5, and 8 for porcine cardiac myosin plus a force producing 0 length step unique
777 to the native in vivo environment. Strain in the active cardiac myosin under load probably lowers
778 measured in vivo step-sizes by affecting the apparent lever-arm rotation angle Φ and also
779 causing the 0 length step. The step-size and step-frequency data from **Fig 7 panels a & b** are
780 interpreted in **Fig 8** showing myosin flux through the 4-pathway network for unloaded,
781 auxotonic, and near-isometric phases of cardiac muscle contraction. Increasing load (smaller net
782 force or velocity v) changes step-frequencies to favor shorter steps such that in near-isometric
783 conditions the long 8 nm step is practically eliminated, the 5 nm step is down-regulated from the
784 unloaded value of 43 to 12%, while the shortest 3 nm step is up-regulated from the unloaded
785 value of 5 to 80% of the total steps (**Table 2**). Uniquely, the 5 then 3 nm step up regulates then
786 down regulates when the muscle transitions from unloaded to isometric phases suggesting its
787 role is to better accommodate rapidly changing force production conditions when the 8 nm step
788 is too long but the 3 nm step is too short to maintain power requirements. That the 3 nm exceeds
789 5 nm step-frequency under high load implied the new mechanism for step-size generation where
790 the 3 nm step contributes both independently and together with the 5 nm step. This is unlike
791 previous assertions that the 3 nm step strictly follows on the 5 nm step based on in vitro work
792 [5]. Increasing load also causes the muscle to make use of the force producing 0 length step that
793 holds tension by remaining strongly actin bound when sliding velocity is near zero. We find that
794 the correlation of rising 0 length and 3 nm step-frequencies with lower 5 and 8 nm step-
795 frequencies and higher resisting force implicates the ELC N-terminus and strained rigor
796 conformation in strain sensing. This observation could be at odds with earlier in vitro motility
797 work looking at strain-dependence in mouse cardiac myosin under load where strain enhanced
798 ATP affinity for actomyosin [44] although loads were short of near-isometric where the ELC
799 ratchet is expected to lower ATP affinity for actomyosin. The video file in S5Movie has an
800 audio/visual description/representation of myosin flux through the 4-pathway network during
801 unloaded, auxotonic, and near-isometric contraction. The written description for the S5 Movie is
802 in S2 File. The latter elaborates on the audio portion of the movie and contains one equation.

803 The proposed mechanisms for strain sensing in vivo, depicted in **Fig 8**, has the ELC
804 ratchet causing the time extended strained rigor state by inhibiting ATP binding, and, the strain
805 dependent ADP release causing the time extended ADP state by inhibiting ADP release. The
806 ELC mediated mechanism accounts for most (42 of 52%) of the total flux into the force

807 producing 0 length step in near-isometric phase. The inhibition efficiency of the strain dependent
808 mechanisms, defined as the flux into the 0 length step divided by the total flux through the
809 contributing pathway, suggests that the strain-dependent ADP release mechanism shuts down
810 flux to the 0 length step pathway from the 5 nm step pathway. Instead the flux travels through
811 the less inhibiting ELC ratchet mediated strain dependent mechanism.

812

813 **Conclusion**

814 Cardiac ventriculum myosin transitioning from low to high force causes motor down-
815 shifting to a 3 nm step-size accounting for >80% of all steps in the near-isometric contraction
816 phase. We propose that strain delays ATP dissociation of actomyosin at isometric force using a
817 mechanism involving the ratcheting effect of the actin bound ELC N-terminus. The significance
818 of ELC N-terminus actin binding follows directly from earlier in vitro single myosin
819 measurements [5, 17] showing close correlation between in vitro and in vivo systems. Enhanced
820 occupation of the 0 length step hints at a mechanism for restrictive cardiomyopathy (RCM)
821 caused by mutation in ELC [45]. Strongly bound myosins fail to detach quickly due to a fault in
822 the ELC N-terminus strain sensing inhibiting detachment under low load conditions. It produces
823 a drag force during stretch when the muscle should be fully relaxed.

824 We explored transduction/mechanical coupling in the beating heart at the single myosin
825 level. High time resolution imaging captures and discriminates the native single myosin behavior
826 during auxotonic and isometric phases of its contractile cycle providing deep insight into the
827 significance of the cardiac myosin strain dependent biochemistry. Overall our approach provides
828 a unique bottom-up assessment of the muscle motor performance by combining high precision
829 single myosin mechanical characterization in an integrated and hierarchically functioning native
830 muscle machine.

831

832 DISCLOSURE

833 We have no competing interests.

834

835 **Supporting information**

836 S1 File. S1 File consists of two figures (A &B) with captions.

837 S2 File. S2 File contains a description of S5 Movie.

838 S1 Movie. S1 Movies contains the video Data147bs(43,171,38,106,90)1.avi.

839 S2 Movie. S2 Movie contains the video Data149bs(190,180,67,121,90)1.avi.

840 S3 Movie. S3 Movie contains the video Data1bs(182,168,98,163,55)1.avi.

841 S4 Movie. S4 Movie contains the video Data230bs(214,217,61,110,45)3.avi.

842 S5 Movie. S5 Movies contains the video Movie5.wmv.

843

844

845 **References**

846

847 **1. Huxley HE. The mechanism of muscular contraction. Science. 1969;164:1356-66.**

848 **2. Pant K, Watt J, Greenberg M, Jones M, Szczesna-Cordary D, Moore JR. Removal**
849 **of the cardiac myosin regulatory light chain increases isometric force production. The**
850 **FASEB Journal. 2009;23:3571-80.**

851 **3. Burghardt TP, Sikkink LA. Regulatory light chain mutants linked to heart disease**
852 **modify the cardiac myosin lever-arm. Biochemistry. 2013;52:1249-59.**

853 **4. Lossie J, Köhncke C, Mahmoodzadeh S, Steffen W, Canepari M, Maffei M, et al.**
854 **Molecular mechanism regulating myosin and cardiac functions by ELC. Biochem Biophys**
855 **Res Commun. 2014;450(1):464-9.**

856 **5. Wang Y, Ajtai K, Kazmierczak K, Szczesna-Cordary D, Burghardt TP. N-terminus**
857 **of Cardiac Myosin Essential Light Chain Modulates Myosin Step-Size. Biochemistry.**
858 **2015;55:186-98.**

859 **6. Burghardt TP, Ajtai K, Chan DK, Halstead MF, Li J, Zheng Y. GFP tagged**
860 **regulatory light chain monitors single myosin lever-arm orientation in a muscle fiber.**
861 **Biophys J. 2007;93:2226-39.**

862 **7. Burghardt TP, Josephson MP, Ajtai K. Single myosin cross-bridge orientation in**
863 **cardiac papillary muscle detects lever-arm shear strain in transduction. Biochemistry.**
864 **2011;50:7809-21.**

- 865 **8. Tokunaga M, Imamoto N, Sakata-Sogawa K. Highly inclined thin illumination**
866 **enables clear single-molecule imaging in cells. Nature Methods. 2008;5:159-61.**
- 867 **9. Huang C-J, Tu C-T, Hsiao C-D, Hsieh F-J, Tsai H-J. Germ-line transmission of a**
868 **myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac**
869 **myosin light chain 2 promoter of zebrafish. Dev Dyn. 2003;228(1):30-40.**
- 870 **10. Sun X, Ekker SC, Shelden EA, Takubo N, Wang Y, Burghardt TP. In vivo**
871 **orientation of single myosin lever-arms in zebrafish skeletal muscle. Biophys J.**
872 **2014;107:1403-14.**
- 873 **11. Burghardt TP, Ajtai K, Sun X, Takubo N, Wang Y. In Vivo Myosin Step-Size from**
874 **Zebrafish Skeletal Muscle. Open Biology. 2016;6:160075.**
- 875 **12. Chen Z, Huang W, Dahme T, Rottbauer W, Ackerman MJ, Xu X. Depletion of**
876 **zebrafish essential and regulatory myosin light chains reduces cardiac function through**
877 **distinct mechanisms. Cardiovasc Res. 2008;79(1):97-108.**
- 878 **13. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, et al. Functional**
879 **Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells. Circ Res.**
880 **2009;104(4):e30-e41.**
- 881 **14. Boulter N, Suarez FG, Schibeci S, Sunderland T, Tolhurst O, Hunter T, et al. A**
882 **simple, accurate and universal method for quantification of PCR. BMC Biotechnology.**
883 **2016;16(1):1-14.**


- 884 **15. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative**
885 **protein structure modeling of genes and genomes. *AnnuRevBiophysBiomolStruct.***
886 **2000;29:291-325.**
- 887 **16. Rayment I, Rypniewski WR, Schmidt-Base K, Smith R, Tomchick DR, Benning**
888 **MM, et al. Three-dimensional structure of myosin subfragment-1: A molecular motor.**
889 ***Science.* 1993;261:50-8.**
- 890 **17. Wang Y, Ajtai K, Burghardt TP. Qdot labeled actin super-resolution motility assay**
891 **measures low duty cycle muscle myosin step-size. *Biochemistry.* 2013;52:1611-21.**
- 892 **18. Steffen W, Smith D, Simmons R, Sleep J. Mapping the actin filament with myosin.**
893 ***Proc Natl Acad Sci USA.* 2001;98:14949-54.**
- 894 **19. Timson DJ, Trayer HR, Trayer IP. The N-terminus of A1-type myosin essential**
895 **light chains binds actin and modulates myosin motor function. *Eur J Biochem.***
896 **1998;255:654-62.**
- 897 **20. Muthu P, Wang L, Yuan C-C, Kazmierczak K, Huang W, Hernandez OM, et al.**
898 **Structural and functional aspects of the myosin essential light chain in cardiac muscle**
899 **contraction. *FASEB J.* 2011;25(12):4394-405.**
- 900 **21. Petzhold D, Simsek B, Meißner R, Mahmoodzadeh S, Morano I. Distinct**
901 **interactions between actin and essential myosin light chain isoforms. *Biochem Biophys Res***
902 ***Commun.* 2014;449(3):284-8.**


- 903 **22. Siemankowski RF, White HD. Kinetics of the interaction between actin, ADP, and**
904 **cardiac myosin-S1. J Biol Chem. 1984;259(8):5045-53.**
- 905 **23. Moczarska A, Kakol I. The influence of regulatory light chains on structural**
906 **organization of cardiac myosin heads interacting with actin and ATP. BiochemMolBiolInt.**
907 **1995;37(4):765-72.**
- 908 **24. Kazmierczak K, Xu YY, Jones M, Guzman G, Hernandez OM, Kerrick WGL, et al.**
909 **The role of the N-terminus of the myosin essential light chain in cardiac muscle**
910 **contraction. J Mol Biol. 2009;387(3):706-25.**
- 911 **25. Wendt T, Taylor D, Trybus KM, Taylor K. Three-dimensional image reconstruction**
912 **of dephosphorylated smooth muscle heavy meromyosin reveals asymmetry in the**
913 **interaction between myosin heads and placement of subfragment 2. Proc Natl Acad Sci**
914 **USA. 2001;98(9):4361-6.**
- 915 **26. Al-Khayat HA, Kensler RW, Squire JM, Marston SB, Morris EP. Atomic model of**
916 **the human cardiac muscle myosin filament. Proc Natl Acad Sci USA. 2013;110(1):318-23.**
- 917 **27. Alamo L, Qi D, Wriggers W, Pinto A, Zhu J, Bilbao A, et al. Conserved**
918 **intramolecular interactions maintain myosin interacting-heads motifs explaining tarantula**
919 **muscle super-relaxed state structural basis. J Mol Biol. 2016;428(6):1142-64.**
- 920 **28. Bobroff N. Position measurement with a resolution and noise-limited instrument.**
921 **Rev Sci Instrum. 1986;57:1152-7.**


- 922 **29. Burghardt TP. Single molecule fluorescence image patterns linked to dipole**
923 **orientation and axial position: Application to myosin cross-bridges in muscle fibers. Plos**
924 **One. 2011;6:e16772.**
- 925 **30. Burghardt TP, Thompson NL. Motion of myosin cross-bridges in skeletal muscle**
926 **fibers studied by time-resolved fluorescence anisotropy decay. Biochemistry. 1985;24:3731-**
927 **5.**
- 928 **31. Burghardt TP, Sun X, Wang Y, Ajtai K. In vitro and in vivo single myosin step-sizes**
929 **in striated muscle. J Muscle Res Cell Motil. 2016:1-15.**
- 930 **32. Wang Y, Ajtai K, Burghardt TP. Ventricular myosin modifies in vitro step-size**
931 **when phosphorylated. J Mol Cell Cardiol. 2014;72:231-7.**
- 932 **33. Piazzesi G, Lucii L, Lombardi V. The size and the speed of the working stroke of**
933 **muscle myosin and its dependence on the force. J Physiol (Lond). 2002;545(1):145-51.**
- 934 **34. Borejdo J, Putnam S, Morales MF. Fluctuations in polarized fluorescence: Evidence**
935 **that muscle cross bridges rotate repetitively during contraction. Proceedings of the**
936 **National Academy of Sciences. 1979;76:6346-50.**
- 937 **35. Irving M, Allen TSC, Sabido-David C, Crank JS, Brandmeyer B, Kendrick-Jones J,**
938 **et al. Tilting of the light-chain region of myosin during step length changes and active force**
939 **generation in skeletal muscle. Nature. 1995;375:688-90.**




- 940 **36. Burghardt TP, Garamszegi SP, Ajtai K. Probes bound to myosin Cys-707 rotate**
941 **during length transients in contraction. Proceedings of the National Academy of Sciences.**
942 **1997;94:9631-6.**
- 943 **37. Reconditi M, Linari M, Lucii L, Stewart A, Sun Y, Boesecke P, et al. The myosin**
944 **motor in muscle generates a smaller and slower working state at higher load. Nature.**
945 **2004;428:578-81.**
- 946 **38. Finer JT, Simmons RM, Spudich JA. Single myosin molecule mechanics:**
947 **piconewton forces and nanometre steps. Nature. 1994;368:113-9.**
- 948 **39. Kaya M, Higuchi H. Nonlinear elasticity and an 8-nm working stroke of single**
949 **myosin molecules in myofilaments. Science. 2010;329(5992):686-9.**
- 950 **40. González-Solá M, Al-Khayat Hind A, Behra M, Kensler Robert W. Zebrafish**
951 **cardiac muscle thick filaments: isolation technique and three-dimensional structure.**
952 **Biophys J. 2014;106(8):1671-80.**
- 953 **41. Jung HS, Komatsu S, Ikebe M, Craig R. Head-head and head-tail interaction: A**
954 **general mechanism for switching off myosin II activity in cells. Mol Biol Cell.**
955 **2008;19(8):3234-42.**
- 956 **42. Hooijman P, Stewart MA, Cooke R. A new state of cardiac myosin with very slow**
957 **ATP turnover: A potential cardioprotective mechanism in the heart. Biophys J.**
958 **2011;100(8):1969-76.**




- 959 **43. Craig R, Padron R, Kendrick-Jones J. Structural changes accompanying**
960 **phosphorylation of tarantula muscle myosin filaments. The Journal of Cell Biology.**
961 **1987;105(3):1319-27.**
- 962 **44. Greenberg MJ, Kazimierczak K, Szczesna-Cordary D, Moore JR. Cardiomyopathy-**
963 **linked myosin regulatory light chain mutations disrupt myosin strain-dependent**
964 **biochemistry. Proc Natl Acad Sci USA. 2010;107(40):17403-8.**
- 965 **45. Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes**
966 **autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive**
967 **physiology. Circulation. 2002;105(20):2337-40.**
- 968
- 969
- 970









**b****c**







8[YgdW]




Figure 8

